Lori Hu is a Managing Director at Vertex Ventures HC (VVHC), leading global healthcare investments based in San Francisco. She joined VVHC in 2015 as part of the founding team to establish a US presence and has led or co-led over a dozen investments across the biotech and medtech sectors. Lori serves on the board of directors for Indapta Therapeutics, Elevation Oncology (NASDAQ: ELEV), Neuspera Medical and Palleon Pharmaceuticals. She is a board observer for Moximed and previously served on the boards of Ivantis (acquired by Alcon for $475M) and Blackthorn (acquired by Neumora). She supported Vertex’s investment in Twelve (acquired by Medtronic for $458 M).
Before VVHC, Lori was an Associate Director for Business Development at Bristol-Myers Squibb, identifying and executing licensing and partnership transactions based in Shanghai. Previously, she was a strategy consultant at Accenture, advising biopharmaceutical clines on strategic projects across the US and Asia.
Lori graduated with an MBA from The Wharton School, and MA in International Studies from the University of Pennsylvania. She also holds a BSE in Biomedical Engineering from Duke University.
